Literature DB >> 10199348

Are clinical trials of therapeutic agents for MS long enough?

P Rudge1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10199348     DOI： 10.1016/S0140-6736(98)00407-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Failures of the therapeutic chain as a cause of drug ineffectiveness.

Authors:  Albert Figueras; Joan-Ramon Laporte
Journal:  BMJ       Date:  2003-04-26

Review 2.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Authors:  D S Goodin; A T Reder; G C Ebers; G Cutter; M Kremenchutzky; J Oger; D Langdon; M Rametta; K Beckmann; T M DeSimone; V Knappertz
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

4.  The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis.

Authors:  Meheroz H Rabadi; Kimberly Just; Chao Xu
Journal:  J Cent Nerv Syst Dis       Date:  2021-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.